PRESS RELEASES More events are coming soon. Keyword Search Year: 202120202019201820172016201520142013 08/09/21 Summary ToggleTRACON Pharmaceuticals Announces Results of Second Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial Printer Friendly PDF Version 08/03/21 Summary ToggleTRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference Printer Friendly PDF Version 07/28/21 Summary ToggleTRACON to Report Second Quarter 2021 Financial Results and Company Highlights on August 11, 2021 Printer Friendly PDF Version 07/21/21 Summary ToggleTRACON Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $15.0 Million Printer Friendly PDF Version 07/21/21 Summary ToggleTRACON Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock Printer Friendly PDF Version 07/20/21 Summary ToggleTRACON Pharmaceuticals Announces Appointment of Brenda Marczi, PharmD, as Senior Vice President, Regulatory Affairs, and Granting of Inducement Award Printer Friendly PDF Version 06/30/21 Summary ToggleTRACON Pharmaceuticals Announces Appointment of Ya Huang as Executive Director of Statistical Programming and Granting of Inducement Award Printer Friendly PDF Version 06/29/21 Summary ToggleTRACON Pharmaceuticals Announces Orphan Drug Designation for Envafolimab in Soft Tissue Sarcoma Printer Friendly PDF Version 06/04/21 Summary ToggleTRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting Printer Friendly PDF Version 06/01/21 Summary ToggleTRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial Printer Friendly PDF Version Pagination First page First Previous page Previous Page 1 Current page 2 Page 3 Page 4 … Next page Next Last page Last
